this is a good study to compare my results of entecavir+antioxidant therapy despite a baseline value of 16.3kpa and cirrhosis and people that just took antiviral.
according to these results antiviral therapy alone has extremely slow effect on fibrosis regression and i do suggest anybody to use antioxidants like i did
my results 1,5 years:
baseline 15.6kpa, pick of 16.3kpa at 4 months after start of therapy, 1.5years after etv+antioxidants 6.3kpa without normal alt (the study defines norma alt less than 30 while i had 40-50 for most of the time)
this study results:
baseline median 7.8kpa (well below cirrhosis, f2-f3), result after 3 years of normal alt......6.1kpa
i bet my fibroscan now is about 5kpa already
Author:
[email protected]
Date: 2011-07-03 23:56 +200
To: hbv_research
Subject: Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study
J Viral Hepat. 2011 Jul;18(7):e200-5. doi: 10.1111/j.1365-2893.2010.01428.x. Epub 2011 Jan 7.
Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study.
Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF.
Source
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Abstract
Summary. For patients with chronic hepatitis B (CHB) infection, changes in liver stiffness measurement (LSM) over time are not known. We examined changes longitudinally in a cohort of patients. Four hundred and twenty-six patients with CHB underwent transient elastography. Patients were followed regularly, and repeat elastography was performed at 3 years. Hepatitis serology, viral load and routine liver biochemistry were monitored. Of the 426 patients, 38 (9%) were hepatitis B e-antigen (HBeAg)-positive, 293 (69%) were HBeAg-negative and 95 (22%) were patients with prior hepatitis B surface antigen (HBsAg) seroclearance. A total of 110 patients received oral antiviral therapy. There was a significant decline of LSMs at the follow-up measurement compared to baseline (6.1 vs 7.8 kPa respectively, P = 0.002) in treated patients who had elevated alanine aminotransferase (ALT) at baseline and subsequent normalization after 3 years (normal ALT limit being 30 U/L for males and 19 U/L for females). In nontreated patients, only the patients with persistently normal ALT at both time points had significantly lower LSMs at the follow-up measurement compared to baseline: 4.9 vs 5.3 kPa, respectively, in patients who remained positive for HBsAg (P = 0.005) and 5.1 vs 5.4 kPa, respectively, in patients who had HBsAg seroclearance (P = 0.026). In patients who remained positive for HBsAg, independent factors associated with a significant decline in LSM of ≥1 kPa included antiviral therapy (P = 0.011) and the ALT levels at the follow-up time point (P = 0.024). Thus, in patients with CHB, a significant decline in LSM after 3 years was observed in treated patients with ALT normalization and in untreated patients who had persistently normal ALT. Antiviral therapy and follow-up ALT levels were independent significant factors associated with a decline in LSM.